Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
September 26, 2023 07:30 ET
|
Theratechnologies
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 millionsBLA for F8 formulation of tesamorelin submitted to FDAAgreement in principle on key amendments to loan facility with...
Theratechnologies présente ses résultats financiers pour le troisième trimestre et les neuf premiers mois de l’exercice 2023 et fait le point sur ses activités commerciales
September 26, 2023 07:30 ET
|
Theratechnologies
Revenus consolidés de 20,9 millions de dollars et BAIIA ajusté de 2,2 millions de dollars au troisième trimestre de 2023Dépôt d’une sBLA relative à la formulation F8 de la tésamoréline auprès de la...
Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company
September 26, 2023 01:00 ET
|
Biocartis NV
PRESS RELEASE:INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST AGREEMENT REGARDING RECAPITALIZATION OF OPERATING SUBSIDIARIES BY SECURED CREDITORS AND WIND DOWN OF LISTED...
Persbericht Biocartis Group NV: Overeenkomst betreffende herkapitalisatie van operationele dochteronderneming door gewaarborgde schuldeisers en liquidatie van beursgenoteerde holdingmaatschappij
September 26, 2023 01:00 ET
|
Biocartis NV
PERSBERICHT: VOORKENNIS / GEREGULEERDE INFORMATIE 26 september 2023, 07:00 CEST OVEREENKOMST BETREFFENDE HERKAPITALISATIE VAN OPERATIONELE DOCHTERONDERNEMINGEN DOOR GEWAARBORGDE SCHULDEISERS EN...
Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization
September 26, 2023 01:00 ET
|
Biocartis NV
PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND...
Persbericht Biocartis Group NV: Biocartis kondigt resultaten H1 2023 aan en geeft een update over de operationele reorganisatie en herkapitalisatie
September 26, 2023 01:00 ET
|
Biocartis NV
PERSBERICHT: VOORKENNIS / GEREGLEMENTEERDE INFORMATIE 26 september 2023, 07:00 CEST BIOCARTIS KONDIGT RESULTATEN H1 2023 AAN EN GEEFT EEN UPDATE OVER DE OPERATIONELE REORGANISATIE EN...
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
September 25, 2023 01:17 ET
|
Novartis Pharma AG
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced...
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
September 22, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the...
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
September 21, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...